Lincoln Pharma reports Q2 FY26 net profit of ₹20.01 crore, approves ₹1.80 dividend for FY24-25
Lincoln Pharma reported Q2 FY26 consolidated net profit of ₹20.01 crore, a 24.06% Y-o-Y decrease. Total income was ₹170.60 crore, down 0.34%. The company approved a ₹1.80 dividend for FY24-25 and targets ₹1,000 crore revenue in three years.
The immediate impact might be tempered by the Q2 year-on-year decline in profit and revenue. However, the approval of a dividend, coupled with strong long-term growth targets, global expansion strategies, and a debt-free status, suggests a medium-term positive outlook for the company, making the overall impact moderate.
While the company reported a year-on-year decline in net profit and total income for Q2 FY26, the half-year results show slight growth in total income and EBITDA. The management's ambitious future growth targets, strategic expansion plans, and a debt-free balance sheet provide a positive outlook, balancing the negative quarterly performance.
* Lincoln Pharmaceuticals Limited reported a consolidated net profit of ₹20.01 crore for the second quarter of FY 2025-26, marking a 24.06% year-on-year decline compared to ₹26.35 crore in Q2 FY25. * Total consolidated income for Q2 FY26 stood at ₹170.60 crore, a slight decrease of 0.34% year-on-year from ₹171.19 crore in Q2 FY25. * Consolidated EBITDA for Q2 FY26 was ₹32.66 crore, down 14.86% year-on-year from ₹38.35 crore in Q2 FY25. Earnings Per Share (EPS) for the quarter was ₹9.98. * For the half year ended September 2025 (H1 FY26), the company reported a consolidated net profit of ₹47.71 crore, a 4.64% year-on-year decline from ₹50.03 crore in H1 FY25. * H1 FY26 consolidated total income grew by 3.36% year-on-year to ₹339.93 crore from ₹328.88 crore in H1 FY25. H1 FY26 consolidated EBITDA increased by 0.34% year-on-year to ₹71.74 crore from ₹71.50 crore in H1 FY25. EPS for H1 FY26 was ₹23.79. * Shareholders, at the 31st Annual General Meeting (AGM) held on September 30, 2025, approved a dividend of ₹1.80 per share (18%) for the financial year 2024-25. * Mr. Mahendra Patel, Managing Director, stated the company aims for ₹1,000 crore revenue within the next three years, targeting a 15-18% annual growth rate. This growth will be driven by expansion into high-value therapeutic segments like cardiac, diabetic, dermatology, and ENT, along with new product introductions and entry into emerging markets. * The company is strengthening its backward integration and export capabilities with the commissioning of a Bulk Drug Manufacturing Plant and progress at its Cephalosporin facility. Lincoln Pharmaceuticals maintains a debt-free balance sheet. * Foreign Institutional Investors (FIIs) have increased their holding in the company to 4.73% as of September 30, 2025. * The company plans to expand its global footprint from over 60 countries to 90 countries in the next 2-3 years, supported by recent entry into the Canadian market and approvals from TGA - Australia and EU GMP.
What to do with a filing like this
Lincoln Pharmaceuticals Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Lincoln Pharmaceuticals Limited. Read the original for the full detail.